SERMS Flashcards

1
Q

excessive exposure to osteorgen is associated

A

with risk of breast cancer
early menarche
late menopause
nulliparty

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ERa

A

always an activator

more important in breast and uterus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ERb

A

sometimes a repressor and more important in CVS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

both ERa and ERb are important for

A

for bone health and CVS protection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

nucelar receptos bind DNA via

A

response elements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NR associated co-factors

A

do the transcriptional modulating
lots of cofactors
have tissues restricted expression patterns, results in increased complexity and tissue specific activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ERb may

A

modulate Era function in breast and uterus

Era appears oncogenic while ERb has tumour suppressor functions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

oestrogens and bone health

A

Era and ERb are expressed in bone and BM cells
increase in estradiol at puberty triggers long bone growth
estradiol maintains bone mineral density in adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

protective effects of estradiol

A

maintains bone miner density in adults

inhibits osteoclasts and promoting osteoblasts and osteocyte survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

SERMS

A

compounds that exhibit tissue-specific ER agonist or antagonist activity
non steroidal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

all SERMs are nonsterodal except

A

fulvestrant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

effects off SERMS

A

varying effects in different tissues but often

  • anti-oostrogenic effect on breast epithelium
  • oestrogenic effect on bone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

SERMS mechanism of action

A

often bigger
prevent helix 12 from closing
co activators can’t bind - pure antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

net agonist/antagonist activity of ER ligands

A

depends on ligand-induced ER conformational changes, ER isoform (a or B) and recruited co-factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

SERMS act as

A

oestrogens on some tissues but anti oestrogens on others

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

first generation SERMS

A

clomiphene

tamoxifen

17
Q

second generation SERMS

A

raloxifene

18
Q

SERMS are used for

A

prevention and treatment of breast cancer
prevention and treatment of osteoporosis
infertility (clomiphene)

19
Q

adjuvant hormone therapy

A

all women with oestrogen receptor positive breast cancer should be considered for adjuvant hormone therapy following surgery
in early breast cancer, its used to eradicate micro metastasis
in advanced breast cancer it is used to improve survival in low volume, bone only metastasis
used to prevent breast cancer in high risk women

20
Q

tamoxifen

A

triphenylethylene
antagonises oestrogen effects on proliferation in breast cancer cells
used to treat oestrogen receptor positive breast cancer

21
Q

tamoxifen in treating breast cancer

A

in metastatic, improved survival
reduction in recurrence
prevention in high risk women

22
Q

tamoxifen in other tissues

A

antagonist in the breast - anti-oestrogen
partial agonist in bone which maintains bone density
cardioprotective - decreases LDL
agonist effect on the epithelium - increased effect of breast cancer
causes iatrogenc menopause

23
Q

ca=ontraindications of tamoxifen

A

do not prescribe if pregnant or breastfeeding, smoker, or history of DVT/PE, stroke

24
Q

raloxifene

A

treat and prevent breast cancer
not as effective as tamoxifen in preventing breast cancer
doesn’t stimulate endometrial proliferation
effects on reproductive tissues vary
breast epithelium - ER antagonist
endometrial epithelium - ER neutral

25
Q

main use of raloxifene

A

osteoporosis

26
Q

raloxifene in bone

A

ER agonist

used to treat osteoporosis n post menopausal women who can’t tolerate biphosphonates

27
Q

aromatase inhibitors

A

anastrozole, letrosole and exemestane
block conversion of androgens to oestrogen
used to treat oestrogen receptor positive breast cancer
survival benefit is greater than tamoxifen

28
Q

side effects of aromatase inhibitor

A

hot flushes
arthralgia
accelerated osteoporosis
so increase n DVTs or endometrial cancer

29
Q

aromatase inhibitor contraindicated in

A

premenopausal women

30
Q

ovarian function suppression

A

continuous GnRH shuts down FSH and LH because those are only triggered when GnRH is pulsatile
goserelin is a GnRH agonist implantat
used in pre menopausal women

31
Q

BC prevention in high risk women

A

tamoxifen

32
Q

BC women in pre menopausal women

A

tamoxifen 10 years

33
Q

BC in post menopausal women low risk

A

tamoxifen

34
Q

BC in post menopausal women high risk

A

aromatase inhibitors